FDA approves Novo Nordisk’s Awiqli as first once-weekly basal insulin for type 2 diabetes
Novo Nordisk (NYSE:NVO) today announced that the U.S. Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae), the first and only once-weekly, long-acting basal insulin for adults living with type 2 diabetes.








_1369156_640x360_2493942339576-640x360.webp&w=3840&q=75)

_1369105_640x360_2493916739746-640x360.webp&w=3840&q=75)
_1369093_640x360_2493917763763-640x360.webp&w=3840&q=75)